Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic agents targeting the melanocortin receptor system. Its primary function centers on addressing unmet medical needs in inflammatory and autoimmune diseases, with a distinct focus on treatments for ocular conditions such as dry eye disease, non-infectious uveitis, and diabetic retinopathy. Palatin has established itself as a pioneer in melanocortin receptor agonist therapies, having brought Vyleesi, a first-in-class treatment for hypoactive sexual desire disorder in premenopausal women, to FDA approval. The company's research pipeline encompasses peptide, peptide mimetic, and small molecule agonist compounds, exploring both injectable and oral formulations. Notably, Palatin actively advances clinical programs for obesity, autoimmune diseases like ulcerative colitis, and various retinal and ocular disorders. Recent strategic collaborations, such as with Boehringer Ingelheim, underscore its role in innovating targeted treatments for retinal diseases. Within the market, Palatin Technologies plays a significant role by advancing specialized therapeutics that aim to resolve inflammation through mechanisms distinct from conventional immunosuppressive drugs.